BVT-115959

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H15N5O5
Molecular Weight	297.2673
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=NC2=C(N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(N)=N1

InChI

InChIKey=AJACDNCVEGIBNA-KQYNXXCUSA-N

InChI=1S/C11H15N5O5/c1-20-11-14-8(12)5-9(15-11)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7-,10-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C11H15N5O5
Molecular Weight	297.2673
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical
Record UNII	E47DV78P45
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

BVT-115959

Common Name

English

2-O-METHYLISOGUANOSINE

Systematic Name

English

ADENOSINE, 2-METHOXY-

Systematic Name

English

NSC-36899

Code

English

SPONGOSINE

Common Name

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

FDA UNII

E47DV78P45

PRIMARY

CAS

24723-77-1

PRIMARY

PUBCHEM

9796227

PRIMARY

EPA CompTox

DTXSID001316127

PRIMARY

NSC

36899

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					E47DV78P45

BVT-115959

ACTIVE MOIETY

Comments:

Biovitrum has completed a first phase 2 study in patients with neuropathic pain. The candidate drug, BVT.115959, is a pH-selective A2A-receptor agonist for the treatment of pain. The results of this first patient study is promising as it shows a high level of safety and tolerability, as well as a positive treatment effect that increased over time. The most important finding in this first phase 2 study is that the unique candidate drug BVT.115959 is very safe and tolerable. Moreover, a positive treatment effect that increased over time was observed although the analysis of the primary variable was not statistically significant. Further analysis of the efficacy data showed statistical significance. The conclusion of these observations is that BVT.115959 has a clear opportunity to show good efficacy and few side-effects in further studies. BVT.115959 decreases inflammation by activating the adenosine receptor 2A in injured tissue. As a consequence of this, BVT.115959 has a potential to fulfil a great medical need to treat chronic pain without giving rise to central nervous system derived side effects.


					E47DV78P45

BVT-115959

ACTIVE MOIETY

Comments:

In contrast, spongosine has demonstrated a diverse bioactivity profile including anti-inflammatory activity, analgesic and vasodilation properties. Investigations into unusual nucleoside production by T. crypta-associated microorganisms using mass spectrometric and spectroscopic techniques has identified a spongosine-producing strain of Vibrio harveyi and several structurally related compounds from multiple strains. These results support a microbial source for the unusual nucleosides originally found in this marine invertebrate, and fermentation of these strains may abrogate the need for sponge collection to acquire these valuable metabolites.


					E47DV78P45

BVT-115959

ACTIVE MOIETY

Comments:

Originator: Cambridge Biotechnology; Developer: Swedish Orphan Biovitrum; Class: Analgesic Mechanism of Action: Adenosine A2 receptor agonist; Highest Development Phase: Discontinued for Inflammatory pain, Neuropathic pain; Most Recent Events: 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum, 07 Apr 2008 Efficacy data from a phase II trial in Neuropathic pain released by Biovitrum, 14 Dec 2007 Biovitrum completes a phase II trial in Neuropathic pain in the Czech Republic, Germany and South Africa

Showing 1 to 3 of 3 entries

Previous1Next